Exposure to Phthalates, BPA May Impact Total 25(OH)D in Adults

This article originally appeared here.
Share this content:
Exposure to Phthalates, BPA May Impact Total 25(OH)D in Adults
Exposure to Phthalates, BPA May Impact Total 25(OH)D in Adults

FRIDAY, Sept. 23, 2016 (HealthDay News) -- Exposure to phthalates and bisphenol A (BPA) may impact circulating levels of total 25-hydroxyvitamin D (25[OH]D), according to a study published online Sept. 20 in the Journal of Clinical Endocrinology & Metabolism.

Lauren E. Johns, M.P.H.S., from the University of Michigan School of Public Health in Ann Arbor, and colleagues examined the correlation between urinary concentrations of 11 phthalate metabolites and BPA and serum 25(OH)D in a cross-sectional study. Data were obtained from the U.S. National Health and Nutrition Examination Survey 2005 to 2010 for adults (aged ≥20 years).

The researchers observed a consistent inverse association for metabolites of di(2-ethylhexyl) phthalate (DEHP) with total 25(OH)D in the study cohort and in gender-stratified models. There was a significant inverse correlation for the molar sum of DEHP metabolites (ΣDEHP), while an increase in ΣDEHP correlated with a 1.90 percent decrease in total 25(OH)D. There was a positive correlation for monoethyl phthalate. A statistically significant inverse association was found for BPA in women, but not men. An increase in interquartile range in urinary BPA correlated with a 3.71 percent decrease in total 25(OH)D in women.

"Our results provide suggestive evidence that environmental exposure to phthalates and BPA may alter circulating levels of total 25(OH)D in adults," the authors write. "Future human and animal studies are required to resolve the direction, temporality, and impact of these relationships."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »